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Introduction
There is a high prevalence of hypogonadism in the
middle- and older-aged male population and various
prevalence ﬁgures have been described in a number of
studies. A consistent feature of these studies is that
hypogonadism increases with age. As the number of
individuals aged 65 years and over in the US popula-
tion is projected to rise from approximately 40 million
(13.0%) in 2010 to approximately 60 million (17.9%)
in 2025, the number of men, who presently comprise
approximately 43% of this population, that are hy-
pogonadal will also increase (1). As a result, physicians
will be increasingly likely to encounter men with the
symptoms of hypogonadism in the clinic.
The purpose of this review is to summarise the
current understanding of male hypogonadism, with
particular reference to the needs of the primary care
physician. A key consideration for any physician is
to understand the clinical signiﬁcance of low testos-
terone levels and how hypogonadal men are likely to
beneﬁt from testosterone replacement therapy. It is
also important to have a good understanding of the
contraindications and risks associated with the ther-
apy as well as the necessary treatment monitoring
required.
Pathophysiology
The Endocrine Society deﬁnes male hypogonadism
as a clinical syndrome that results from failure of the
testis to produce physiological levels of testosterone
(androgen deﬁciency) and the normal number of
spermatozoa caused by disruption of one or more
levels of the hypothalamic–pituitary–gonadal (HPG)
axis (2).
There are other deﬁnitions published by the Amer-
ican Association of Clinical Endocrinologists (AACE)
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SUMMARY
There is a high prevalence of hypogonadism in the older adult male population
and the proportion of older men in the population is projected to rise in the
future. As hypogonadism increases with age and is signiﬁcantly associated with
various comorbidities such as obesity, type 2 diabetes, hypertension, osteoporosis
and metabolic syndrome, the physician is increasingly likely to have to treat hypog-
onadism in the clinic. The main symptoms of hypogonadism are reduced
libido⁄erectile dysfunction, reduced muscle mass and strength, increased adiposity,
osteoporosis⁄low bone mass, depressed mood and fatigue. Diagnosis of the condi-
tion requires the presence of low serum testosterone levels and the presence of
hypogonadal symptoms. There are a number of formulations available for testoster-
one therapy including intramuscular injections, transdermal patches, transdermal
gels, buccal patches and subcutaneous pellets. These are efﬁcacious in establishing
eugonadal testosterone levels in the blood and relieving symptoms. Restoration of
testosterone levels to the normal range improves libido, sexual function, and
mood; reduces fat body mass; increases lean body mass; and improves bone min-
eral density. Testosterone treatment is contraindicated in subjects with prostate
cancer or benign prostate hyperplasia and risks of treatment are perceived to be
high by many physicians. These risks, however, are often exaggerated and should
not outweigh the beneﬁts of testosterone treatment.
Review Criteria
• We summarise information that primary care
physicians need to know about this common
condition, found in 20–40% of older men.
• Articles were identiﬁed from MEDLINE in May–
September 2009 (search limits; last 10 years,
humans, English language) using the terms
testosterone and hypogonadism.
• In general, we cite articles that review a broad
range of hypogonadal comorbidities as well as
professional societies’ guidelines for testosterone
diagnosis, treatment options and monitoring
procedures.
Message for the Clinic
• Physicians must be alert to the fact that many
of their patients may be suffering from low
testosterone levels.
• Hypogonadism increases with age and is
particularly associated with some of the most
common conditions found in patients visiting
primary care clinics, such as diabetes and obesity.
• Physicians need to know the symptoms of
hypogonadism and the various testosterone
replacement treatment options.
Linked Comment: Jackson. Int J Clin Pract 2010; 64: 663–4.
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682 doi: 10.1111/j.1742-1241.2010.02355.x(3) and the various international and European soci-
eties of andrology and urology (4). The condition
has a number of different names reﬂecting differing
opinions (5) (Table 1). The different names have
arisen as authors try to separate the hypogonadism
resulting from natural ageing from, for example, the
hypogonadism caused by testicular trauma. In this
review, hypogonadism will be used as a general term
to refer to any state characterised by low blood tes-
tosterone levels.
Testosterone regulation in the eugonadal male
Androgens are vital for the maintenance and devel-
opment of sexual function in men. The regulation of
testosterone production in eugonadal men depends
on the HPG axis depicted in Figure 1. The hypothal-
amus secretes gonadotropin-releasing hormone
(GnRH) that acts on the anterior pituitary to
produce follicle-stimulating hormone (FSH) and
luteinizing hormone (LH). LH acts on the interstitial
Leydig cells of the testes, stimulating them to
produce testosterone, whereas FSH stimulates sper-
matogenesis and Sertoli cell function (6,7).
Secretion of LH from the pituitary is not constant,
but has approximately six bursts of secretion per day
with an early morning high and an early evening
low. A total of approximately 7 mg of testosterone is
secreted each day (8), although in older men the rate
decreases (9).
Only 1–2% of testosterone circulates free in the
blood; the remaining 98–99% is bound to albumin
(40–50%) and to sex hormone binding globulin
(SHBG) (50–60%). Testosterone binds strongly to
SHBG, and it is therefore largely the free and
albumin-bound testosterone that is available for
biological action (10). For this reason, free and
albumin-bound testosterones together are termed
bioavailable testosterone (BAT).
The HPG axis is regulated by a negative feedback
mechanism (Figure 1). Testosterone inhibits the fre-
quency and amplitude of GnRH release from the
hypothalamus and also the secretion of LH from the
pituitary. The Sertoli cells of the testes, in addition
to stimulating spermatogenesis, also secrete the gly-
coprotein hormone inhibin, which provides negative
feedback to the pituitary, inhibiting the secretion of
FSH (11).
Testosterone is converted to dihydrotestosterone
(DHT) by 5a-reductase enzymes or to estradiol by
aromatase in target cells. Testosterone and DHT both
bind to the androgen receptor where they exert their
biological effects. Approximately 20% of the DHT in
the circulation is produced directly by testicular
secretion, with the remaining 80% being derived
from conversion from testosterone in the peripheral
tissues (10).
Target cells that contain 5a-reductase are concen-
trated in the prostate, reproductive system and skin.
Aromatase-containing cells predominate in the liver
and adipose and regions of the brain (6,12).
Testosterone and other androgens have important
biological and physiological effects, summarised in
Table 2. Apart from the vital role that it plays during
puberty in stimulating the development of male sec-
ondary sexual characteristics and their maintenance
thereafter, it has multiple other physiological effects.
These include the promotion of haemoglobin synthe-
sis and red blood cell production; the stimulation of
anabolic muscular development and bone growth;
and the suppression of adipose tissue formation.
Testosterone also stimulates the basal metabolic rate
(8) and has positive effects on mood and cognitive
ability (13). Behavioural effects include mediating
sexual behaviour and competitive encounters (14),
Table 1 Alternative names for male hypogonadism
(2,4,77,98)
Androgen deﬁciency syndrome
Androgen deﬁciency in the ageing male (ADAM)
Andropause
Late-onset hypogonadism
Male menopause
Partial androgen decline in the ageing male (PADAM)
Testosterone deﬁciency syndrome
Seminiferous tubules
FSH
Sertoli cells Leydig cells
Spermatozoa Testosterone
Hypothalamus
GnRH
Anterior pituitary
Testis
LH
–
–
Figure 1 The hypothalamic–pituitary–gonadal axis in men.
GnRH, FSH, and LH have stimulatory effects on their
targets. Testosterone inhibits their release from the
hypothalamus and the pituitary. FSH, follicle-stimulating
hormone; GnRH, gonadotropin-releasing hormone; LH,
luteinizing hormone
Male hypogonadism in the primary care setting 683
ª 2010 Blackwell Publishing Ltd Int J Clin Pract, May 2010, 64, 6, 682–696for example, a connection between ﬁnancial proﬁts
and raised endogenous testosterone levels has been
described for male commodity traders in the City of
London (15).
Primary hypogonadism
Primary hypogonadism is caused by testicular failure
and is characterised by low serum testosterone and
high LH and FSH concentrations. For this reason,
primary hypogonadism is also known as hypergona-
dotropic hypogonadism. Primary hypogonadism can
result from testicular injury, tumour, or infection;
genetic defects affecting testicular development (e.g.
Klinefelter syndrome), as well as chemotherapy, radi-
ation treatment or alcohol abuse (3,16).
Secondary hypogonadism
In secondary hypogonadism (hypogonadotropic hyp-
ogonadism), defects in the hypothalamus or pituitary
result in low testosterone levels because of insufﬁ-
cient stimulation of the Leydig cells. It is also associ-
ated with low or low-normal FSH and LH levels.
Patients with secondary hypogonadism can have
their fertility restored by suitable hormonal stimula-
tion, whereas those with primary hypogonadism
resulting from testicular failure cannot. Secondary
hypogonadism can be caused by a number of
conditions (Table 3) including hypothalamic and
pituitary disorders or lesions, hyperprolactinemia
and Kallmann syndrome (which causes a GnRH
deﬁciency) (16). Certain medications and illnesses
can also affect the hypothalamic–pituitary system
resulting in hypogonadism (17).
It should be noted that low testosterone can be
caused by a combination of both primary and
secondary hypogonadism (also called mixed hypog-
onadism) that reﬂects defects in the hypothalamus
and⁄or the pituitary as well as the testes. This is
found in men with sickle-cell disease, thalassemia,
alcoholism, glucocorticoid treatment, and in older
men (2). In general, however, the term mixed
hypogonadism is not used in clinical practice in
the US and is considered part of secondary hypog-
onadism.
Prevalence and comorbidities
Prevalence of hypogonadism
In the Baltimore Longitudinal Study on Ageing, it
was found that 19% of men over 60 years had low
testosterone. The Hypogonadism in Males (HIM)
study estimated the overall prevalence of hypogona-
dism at approximately 39% in men aged 45 years or
older (18). It has been estimated that only 5–35% of
hypogonadal males actually receive treatment for
their condition (19,20).
Measuring testosterone levels in populations, while
useful, is different from measuring hypogonadal
symptoms. A subject can have low testosterone levels,
but can also have no clinically signiﬁcant symptom-
atology. Likewise, measurement of symptoms alone
is not reliable, as hypogonadal symptoms are non-
speciﬁc. The Massachusetts Male Ageing Study
(MMAS) measured a combination of testosterone
levels and hypogonadal symptoms and found
between 6% and 12% of men had symptomatic
androgen deﬁciency (21). An interesting observation
Table 2 Physiological effects of testosterone in male
adults (6)
Maintains reproductive tissues
Stimulates spermatogenesis
Stimulates and maintains sexual function
Increases body weight and nitrogen retention
Increases lean body mass
Maintains bone mass
Promotes sebum production, and axillary and body hair growth
Stimulates erythropoiesis
Table 3 Causes of male hypogonadism (3,16,76)
Primary hypogonadism
Congenital anorchidism
Cryptorchidism
Mumps orchitis
Genetic and developmental conditions: Klinefelter syndrome,
androgen receptor and enzyme
Defects, Sertoli cell only syndrome
Radiation treatment⁄chemotherapy
Testicular trauma
Autoimmune syndromes (anti-Leydig cell disorders)
Secondary hypogonadism
Genetic conditions: Kallmann’s syndrome, Prader-Willi
syndrome
Pituitary tumours, granulomas, abscesses
Hyperprolactinemia
Cranial trauma
Radiation treatment
Various medications
Mixed (primary and secondary) hypogonadism*
Alcohol abuse
Ageing
Chronic infections (HIV)
Corticosteroid treatment
Hemochromatosis
Systemic disease (liver failure, uremia, sickle-cell disease)
*Mixed hypogonadism is often included within the secondary
hypogonadism category.
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have symptomatic androgen deﬁciency at one stage
were found to be eugonadal when retested at a later
stage (22). This is probably because there is subject-
to-subject variation in testosterone secretion and in
the testosterone threshold where symptoms become
manifest. As discussed below, a measurement of low
testosterone in a patient should be reconﬁrmed at a
later stage before considering treatment.
Older men are more likely to have low testoster-
one levels: in the HIM study, for example, the preva-
lence of low testosterone in the 45–54 age group was
34%, whereas it was 50% in men over 85 years (18).
Likewise, in the Baltimore study the percentage of
men with low testosterone increased from 12% in
men in their 50s, to 49% in men over 80 years of
age (23).
There appears to be no consistent evidence that
the prevalence of hypogonadism differs between
racial and ethnic groups (24–26).
Common comorbidities
Higher rates of hypogonadism than those in the gen-
eral population are associated with various common
diseases or conditions. The HIM study calculated
odds ratios for some common conditions (Table 4).
It is not yet understood whether the low testosterone
levels are a consequence of the disease, are connected
with the disease’s aetiology, or are one of the causes
of the disease. Further studies are needed to deter-
mine if treating the associated hypogonadism is likely
to improve the patient’s disease symptoms.
Cardiovascular disease
Vascular tissue (including endothelium and vascular
smooth muscle cells) contains androgen receptors, so
it is to be expected that testosterone (or its metabo-
lite, oestrogen) is likely to affect the cardiovascular
system. In fact, the increased risk of cardiovascular
disease in males compared with females has been
taken to imply a role for testosterone (or oestrogen)
in the disease. Human observational studies, how-
ever, have shown no associations between high
testosterone levels and coronary artery disease, and
testosterone has been shown to dilate the coronary
arteries both in vitro and in vivo. Some studies have
shown that testosterone can be considered to have a
positive effect on reducing the risk factors for cardio-
vascular disease; for example, inverse relationships
have been shown between testosterone levels and
body mass index (BMI), waist circumference, waist-
hip ratio, serum leptin, low-density lipoprotein
(LDL) cholesterol, triglyceride and ﬁbrinogen levels.
Low testosterone is associated with dyslipidemia,
hypertension, obesity and diabetes, all of which
increase the risk of cardiovascular disease and are
features of the metabolic syndrome (27,28).
A negative view of testosterone’s impact on
cardiovascular disease comes from the observation
that high-density lipoprotein (HDL) cholesterol levels
decrease in patients on oral testosterone therapy, or
when taken in supraphysiological doses by athletes
(29,30). However, when given as a transdermal gel to
hypogonadal men, there is either no signiﬁcant
change or only minor changes in HDL levels
(28,31,32). Whatever the subtleties of the effects of
testosterone on lipids, recent data have demonstrated
that low testosterone concentrations are associated
with an increased incidence of cardiovascular events,
and an increase in acute myocardial infarction and
stroke.
The relationship between testosterone and HDL is
confounded by the fact that both HDL and testoster-
one are inversely related to BMI. In fact, epidemio-
logical analyses have found that HDL levels are
positively linked to testosterone levels in middle-aged
men. Data from the MMAS have demonstrated that
there is a strong, positive relationship between HDL
and testosterone in men with cardiovascular disease
(low total or free testosterone correlates with low
HDL cholesterol) (31).
Recent work in the Rancho Bernardo, California
population has shown that men with serum total tes-
tosterone levels in the lowest quartile (< 241 ng⁄dl)
were associated with a higher risk (38%) of cardio-
vascular mortality, compared with those who have
higher total testosterone levels, independent of age,
obesity and lifestyle choices (33). In fact, those with
low testosterone were 40% more likely to die
(all-cause mortality) than those with higher levels.
This is in contrast to what was found in the MMAS
study where total testosterone levels were unrelated
to all-cause mortality (34,35).
A meta analysis, published in 2007, of randomised
trials that assessed the effect of exogenous testoster-
one on cardiovascular events, however, concluded
that the inference that testosterone use in men is not
associated with important cardiovascular effects was
Table 4 Odds ratios for hypogonadism for various
comorbidities from the HIM Study (18)
Condition Odds ratio
Obesity 2.38
Diabetes 2.09
Hypertension 1.84
Hyperlipidaemia 1.47
Osteoporosis 1.41
Asthma⁄chronic obstructive pulmonary disease 1.40
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men with and without cardiovascular disease and
with cardiovascular end-points are needed to better
assess the consequences of testosterone treatment on
cardiovascular risk (36).
A recent study (2009) from Italy demonstrates that
testosterone treatment in elderly patients with
chronic heart failure improves insulin sensitivity and
various cardiorespiratory and muscular outcomes
(37).
Diabetes
In 2007, it was estimated that 23.6 million people, or
7.8% of the US population, had diabetes (38). Pro-
jections based on data from the National Health and
Nutrition Examination Surveys (NHANES) show
that by 2021 there are anticipated to be approxi-
mately 33 million people with diabetes in the United
States, representing 13.5% of the population (39).
Low testosterone concentrations are known to
occur in association with type 2 diabetes. However,
clinicians have often not related low testosterone
concentrations to clinical hypogonadism. The ﬁrst
attempt to measure free testosterone and to establish
hypogonadism as a feature of male type 2 diabetes
was made by Dhindsa et al. in 2004 (40). This has
been conﬁrmed in several other studies including the
HIM study (41). In the HIM study, a diabetic man
was approximately twice as likely to be hypogonadal
compared with a non-diabetic man (18). Prevalence
in diabetic men has been estimated at 33–50%
(18,40,42). With such a high prevalence, hypogona-
dism is a candidate for the most common com-
plication of male type 2 diabetes. Analysis of
gonadotropin levels demonstrates that the hypogona-
dism in type 2 diabetes is mostly hypogonadotropic
(secondary) hypogonadism (40). There is no relation
between the degree of hyperglycaemia and testoster-
one concentration (40,43).
C-reactive protein, a marker for systemic inﬂam-
mation, has been found to be markedly elevated in
patients with secondary hypogonadism and type 2
diabetes. The concentrations of C-reactive protein in
these patients are twice as high as those in eugonadal
type 2 diabetics, whose C-reactive protein levels are
already elevated compared with non-diabetics. Such
patients have also been shown to have mild anaemia,
low bone mineral density (BMD) in the arms and
ribs, and increased adiposity when compared with
eugonadal type 2 diabetics (44,45). These features are
similar to those of hypogonadal patients without dia-
betes. Another intriguing observation is that pros-
tate-speciﬁc antigen (PSA), a marker for prostate
cancer, is signiﬁcantly lower in type 2 diabetics and
this is related to their lower plasma testosterone
concentrations (46). The clinical signiﬁcance of this
remains to be elucidated.
Interestingly, low testosterone concentrations pre-
dict the development of type 2 diabetes. Utilising
data from the NHANES III survey, it was found that
men in the lowest free testosterone tertile were four
times as likely to have diabetes as those in the high-
est free testosterone tertile (47).
Type 1 diabetes does not seem to be associated
with hypogonadism, suggesting that hypogonadism is
speciﬁc to type 2 diabetes and not related speciﬁcally
to hyperglycaemia (43).
Obesity and the metabolic syndrome
Obesity amongst adult men had a prevalence of
33.3% in 2005–2006 according to the most recent
NHANES review (48). An adult who has a BMI
between 25 and 29.9 kg⁄m
2 is considered overweight,
whereas an adult who has a BMI of 30 kg⁄m
2 or
higher is considered obese. This is not a rigid rule as
BMI does not directly measure body fat, so athletes,
for example, may have high BMIs even though they
are not overweight (49).
The health risks associated with obesity are well
known, increasing the risk for type 2 diabetes, hyper-
tension, atherosclerotic diseases and coronary heart
disease. Obesity is strongly associated with type 2
diabetes: approximately 83% of diabetic patients are
overweight or obese (50). Obesity is also associated
with low total testosterone and reduced SHBG levels.
There is an inverse linear relationship between total
testosterone and BMI, and free testosterone concen-
trations also decrease with increasing BMI. There is
an inverse relationship between serum total and free
testosterone levels and visceral fat mass. Thus, the
degree of hypogonadism is positively correlated to
the degree of obesity in obese men (51,52).
A person with metabolic syndrome is deﬁned as
having central obesity in addition to any two of these
four factors: hypertension (‡ 130⁄85 mm Hg),
reduced HDL (< 40 mg⁄dl in males), raised triglyce-
rides (‡ 150 mg⁄dl) or raised fasting plasma glucose
(‡ 100 mg⁄dl)(53). It is considered a high risk for
coronary heart disease (19,54). As the constituent
elements of metabolic syndrome are themselves cor-
related with testosterone concentrations, it is perhaps
not surprising that hypogonadism is also associated
with the metabolic syndrome, as has been shown in
a number of epidemiological studies (55,56).
Low testosterone levels are correlated with insulin
resistance in both epidemiological and interventional
studies, and this may be attributable to the effect of
testosterone on adiposity. Low testosterone levels
increase fat mass and decrease lean muscle, resulting
in increased adipose tissue (52).
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increasing the aromatisation of testosterone to estra-
diol, because the aromatase enzyme is concentrated
in adipocytes. This reduces serum and tissue testos-
terone levels. The estradiol produced by aromatisa-
tion also provides negative feedback on the HPG
axis, further reducing testosterone. Thus, adiposity
potentially leads to hypogonadism, which itself pro-
motes further adiposity. Figure 2 illustrates the main
hypogonadal-obesity-insulin resistance connections
and also includes other factors such as TNF-a (an
adipokine), which is elevated in obese males
(42,51,57,58).
However, it seems likely that testosterone may
suppress insulin resistance independently of its effects
on adiposity. The withdrawal of testosterone therapy
in hypogonadal patients that had been stabilised on
this therapy leads to an increase in insulin resistance
within 2 weeks and prior to signiﬁcant weight gain
(59). A recent study showed that supervised diet and
exercise increased testosterone levels in hypogonadal
men with metabolic syndrome and newly diagnosed
type 2 diabetes. In addition, a small dose
(50 mg⁄day) of testosterone gel improved both gly-
cemic control and insulin sensitivity over and above
the improvements because of diet and exercise (60).
The mechanism underlying the insulin sensitising
effects of testosterone needs to be elucidated.
An important proviso to this discussion is that
further research into the role of hypogonadism in
obesity, metabolic syndrome and diabetes is required
to gain a better understanding of the pathogenic
mechanisms involved and that, at present, it is not
known whether hypogonadism is the cause or the
consequence of these conditions.
Osteoporosis
Osteoporosis is an under-recognised problem in
men. Ten to twenty per cent of individuals with
osteoporosis over 50 years old in the United States
are men (25). Up to 13 million men are at increased
risk because of low BMD and up to 2 million of
these have osteoporosis (61,62). Men have almost
30% of all hip fractures and men are twice as likely
to die in hospital than women after a hip fracture.
Hip fracture incidence is low until after 75 years,
when the risk increases exponentially. Vertebral frac-
tures are also common, although they are only about
half as common in men compared with women (63).
There are many suspected causes of osteoporosis,
and the most frequent are corticosteroid use, Cush-
ing’s syndrome, hypogonadism and excessive alcohol
consumption. In a study of elderly men in a nursing
home who have experienced hip fractures, 66% were
hypogonadal (64).
Other common secondary causes are smoking, low
calcium intake and vitamin D deﬁciency or insufﬁ-
ciency (61).
Various epidemiological studies in men have
examined associations between testosterone and
estradiol levels and BMD. Estradiol levels in men
have been consistently and positively associated with
BMD. Testosterone is also positively associated with
BMD, but the relationship is weaker than that of
estradiol (65,66).
Interventional studies have shown that testosterone
replacement therapy in hypogonadal males increased
spine BMD and trabecular connectivity (61,67).
However, studies of testosterone therapy in men with
osteoporosis are limited and none have used frac-
tures as an end-point; so although there is signiﬁcant
evidence of an association between hypogonadism
and osteoporosis, there is no established causal link
between the two.
Complications of treatment for other
conditions
Corticosteroid treatment
Testosterone levels are lower in men being treated
with corticosteroids. Systemic glucocorticoids can
Hypothalamus pituitary
Adipose
tissue
Leydig cells
Testosterone
Leptin
Inhibition         Lower production
Insulin
resistance
–
–
–
–
–
Estradiol
Adipokines LH
Figure 2 The interrelationship between hypogonadism and
insulin resistance (after (42,51)). LH, luteinizing hormone.
Low testosterone stimulates an increase in adiposity.
Adipose tissue contains high concentrations of aromatase,
which reduces testosterone concentrations by converting it
to estradiol. The estradiol negatively feeds back on the
HPG system, reducing testosterone production in the
Leydig cells. Increasing adipose tissue increases insulin
resistance, which negatively impacts the Leydig cells as well
as inhibiting the release of luteinizing hormone (LH) via
the release of adipokines (inﬂammatory cytokines) such as
TNF-a. Leptin, released in response to increased adiposity,
also inhibits the release of LH via its effect on the release of
gonadotropin-releasing hormone
Male hypogonadism in the primary care setting 687
ª 2010 Blackwell Publishing Ltd Int J Clin Pract, May 2010, 64, 6, 682–696reduce testosterone biosynthesis in the testis; in
addition, glucocorticoids impact the HPG axis by
inhibiting the release of LH (17,68). As a result,
patients being treated with glucocorticoids for such
chronic conditions as rheumatoid and osteoarthritic
inﬂammation, skin inﬂammations, asthma, chronic
obstructive pulmonary disease (COPD) and inﬂam-
matory bowel disease are at an increased risk of
hypogonadism.
There have been some studies that suggest that
COPD patients have a higher incidence of hypogona-
dism than the general population and that glucocor-
ticoid treatment is only part of the reason. The
pathophysiology of this remains unclear, but sugges-
tions have been made that it might be connected
with chronic hypoxia, and a systemic inﬂammatory
response (68). A number of studies have shown that
testosterone therapy can improve lean body mass
and BMD and strength in hypogonadal men with
COPD (17).
Chronic pain treatment
Long-acting opioids such as methadone, morphine
sulphate, fentanyl and oxycodone for the treatment
of chronic pain often result in opioid-induced
androgen deﬁciency (OPIAD). In a case–control
study of 40 cancer survivors it was found that 90%
of those on opioid treatment were hypogonadal
compared with only 40% of the control group (69).
The mechanism for OPIAD is thought to involve
suppression of GnRH release by the hypothalamus,
thereby inducing secondary hypogonadism (17,70).
Cancer
Apart from the effects of testicular cancers, which
may have a direct impact on testosterone secretion,
the prolonged radiation treatment, chemotherapy
using antimitotic drugs or corticosteroids or pain
treatment medications characteristic of cancer treat-
ment are likely to induce hypogonadism (17). These
drugs may induce Leydig cell dysfunction or germi-
nal epithelial failure (71). The HPG axis may also be
affected by androgen-, or ectopic adrenocorticotropin
hormone-producing tumours, leading to secondary
hypogonadism (17).
HIV
Androgen deﬁciency is strongly associated with
AIDS wasting syndrome, and testosterone therapy in
HIV-positive hypogonadal men increases lean body
and muscle mass and perceived well-being, and
decreases depression (72–74). Approximately 20–50%
of HIV-infected men receiving highly active antiret-
roviral therapy are hypogonadal. While these preva-
lence levels may superﬁcially appear similar to the
background ﬁgures in the population, most studies
are based on middle-aged populations. HIV patients
with AIDS are younger and therefore, comparisons
have to be carried out with appropriately age-
matched controls.
The cause of this hypogonadism is probably as a
result of a number of factors, including lipodystro-
phy induced by highly active retroviral medications;
testicular atrophy caused by opportunistic infection;
disruption of the HPG axis resulting from malnutri-
tion; and the results of medications such as the an-
timycotic ketoconazole, which inhibits steroid
biosynthesis (17).
Clinical presentation and diagnosis
Symptoms
There are a number of symptoms and signs related
to low testosterone concentrations that indicate a
diagnosis of hypogonadism. The clinical practice
guidelines by the Endocrine Society (2) and the
AACE (3) suggest that physicians should measure the
testosterone levels of men with any of the symptoms
and signs outlined in Table 5.
Screening tools can be helpful in identifying
patients with a high probability of having low testos-
terone. The Androgen Deﬁciency in Ageing Males
(ADAM) questionnaire can be helpful to initiate
a conversation about the symptoms they may be
Table 5 Symptoms and signs of hypogonadism (2,99)
Primary symptoms
Reduced libido
Lack of effect of PDE5 inhibitors for erectile dysfunction
Reduced muscle mass and strength
Depressed mood
Decreased energy or vitality; increased fatigue
Osteoporosis or low bone mass
Other symptoms and signs suggestive of low
testosterone
Incomplete sexual development, eunuchoidism, aspermia
Decreased spontaneous erections
Breast discomfort, gynaecomastia
Loss of body (axillary and pubic) hair; reduced shaving
Very small or shrinking testes (especially < 5 ml)
Inability to father children; low or zero sperm counts
(oligospermia or azoospermia)
Low trauma fracture, low bone mineral density
Poor concentration and memory
Sleep disturbance; increased sleepiness
Mild anaemia (normochromic, normocytic, in the female
range)
Increased body fat, body mass index
Diminished physical or work performance
Menopausal-type hot ﬂushes
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that screening questionnaires such as ADAM should
never be used in isolation to diagnose clinical hypog-
onadism.
The symptoms most associated with hypogona-
dism are low libido, erectile dysfunction (ED),
decreased muscle mass and increased body fat,
decreased BMD, decreased vitality, and depressed
mood. None of these symptoms is unique to hypog-
onadism, so one or more of these symptoms must be
combined with a low testosterone concentration for
the diagnosis to be made.
Although the Endocrine Society does not suggest
routine screening of non-symptomatic at-risk
patients, physicians need to be aware of the high
prevalence of low testosterone with other conditions,
discussed earlier in this review, such as type 2 diabe-
tes, HIV, and COPD, as well as end-stage renal dis-
ease, which are all high risk factors for
hypogonadism (Table 7). In our opinion, screening
for at-risk patients is therefore worthy of consider-
ation.
Diagnosis
Figure 3 shows an algorithm for the diagnosis of
hypogonadism (2,76,77). The Endocrine Society rec-
ommends that the diagnosis of testosterone be made
in men who have both consistent signs and symp-
toms and low total testosterone levels. Serum total
testosterone is the easiest and most straightforward
measurement to take for the ﬁrst measurement. Most
hospital laboratories can provide total testosterone
measurements of good accuracy and reliability. As
testosterone is subject to circadian and circannual
rhythms it is recommended to draw the blood
sample in the morning. There are no absolute testos-
terone levels below which a man can unambiguously
be stated to be hypogonadal. The Endocrine Society
recommends 300 ng⁄dl (10.4 nmol⁄l) as a good level
to consider as the lower limit of normal total testos-
terone. The AACE suggests 200 ng⁄dl (3), and the
International Society of Andrology (ISA), Interna-
tional Society for the Study of Ageing Male (ISSAM),
European Association of Urology (EAU), European
Academy of Andrology (EAA), American Society
of Andrology (ASA) recommendations suggest
230 ng⁄dl is a limit below which patients will usually
beneﬁt from testosterone replacement treatment (4).
Total testosterone represents the total of free,
SHBG-bound, and albumin-bound testosterone.
SHBG levels are easily affected by many conditions,
so total testosterone measurements can therefore be
misleading indicators of hypogonadism. Table 8 gives
a list of conditions when SHBG levels may be higher
or lower than normal. As obese or elderly men are
Table 6 Androgen deﬁciency in ageing males (ADAM)
questionnaire (75)
1. Do you have a decrease in libido (sex drive)?
2. Do you have a lack of energy?
3. Do you have a decrease in strength and⁄or endurance?
4. Have you lost height?
5. Have you noticed a decreased enjoyment of life?
6. Are you sad and⁄or grumpy?
7. Are your erections less strong?
8. Have you noticed a recent deterioration in your ability to
play sports?
9. Are you falling asleep after dinner?
10. Has there been a recent deterioration in your work
performance?
If the answer is ‘yes’ to question 1 or 7, or at least 3 of the
other questions, low testosterone may be present.
Table 7 Conditions requiring measurement of serum
testosterone (as suggested by the Endocrine Society) (2)
Infertility
Osteoporosis, low trauma fracture
Type 2 diabetes mellitus
Glucorticoid, ketoconazole, opioid or other medications that
affect T metabolism or production
Moderate to severe COPD
Sellar mass, radiation to the sellar region, or other diseases of
the sellar region
End-stage renal disease, maintenance haemodialysis
HIV-associated weight-loss
COPD, chronic obstructive pulmonary disease.
History and physical exam
<300 ng/dl >300 ng/dl
<300 ng/dl >300 ng/dl
Seek other causes
Symptoms
Patient with suspected low T
Measure morning TT Levels
Low T
Low T
Normal T
Normal T
Remeasure morning TT
Refer to endocrinologist
Diagnosis of hypogonadism
Figure 3 An algorithm for the diagnosis of hypogonadism
(2,76,77). TT, total testosterone
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dent not to rely on total testosterone concentrations
for diagnosing low testosterone concentrations for
these patients. We therefore recommend that you
should consider free testosterone or BAT measure-
ments in all men other than healthy lean young men
(whose SHBG levels are presumably normal and
whose measured total testosterone concentration is
reliable).
It is important that physicians use reliable labora-
tories and that they are aware of their reference
ranges for testosterone. For a primary care physician,
it might be considered appropriate to refer a patient
who requires further testosterone tests to an endocri-
nologist. If referral is not possible, one can calculate
free testosterone reliably by using total testosterone,
albumin and SHBG concentrations using an online
calculator (http://www.issam.ch/freetesto.htm) or
measure free testosterone accurately in a laboratory
by equilibrium dialysis. As with total testosterone
measurements, there is no general agreement as
to what constitutes the lower limit of normal free
testosterone levels, but the Endocrine Society
mentions 50 pg⁄ml for free testosterone measured by
equilibrium dialysis and the ISA, ISSAM, EAU, EAA
and ASA recommend 65 pg⁄ml for calculated free
testosterone.
The ISA⁄ISSAM⁄EAU⁄EAA⁄ASA guidelines sug-
gest that subjects with total testosterone levels falling
between 230 and 350 ng⁄dl (8–12 nmol⁄l) could
beneﬁt from having a repeat measurement of total
testosterone together with a measurement of SHBG
concentrations so as to calculate free testosterone
levels, or free testosterone levels can be measured
directly via equilibrium analysis in these cases (4).
The ﬁnal step in determining whether a patient
has primary or secondary hypogonadism is measur-
ing the serum LH and FSH. Elevated LH and FSH
levels suggest primary hypogonadism, whereas low or
low-normal LH and FSH levels suggest secondary
hypogonadism. Normal LH or FSH levels with low
testosterone suggest primary defects in the hypothal-
amus and⁄or the pituitary (secondary hypogona-
dism). Unless fertility is an issue, it is usually not
necessary to measure FSH and determining LH levels
alone is sufﬁcient. In secondary hypogonadism,
prolactin levels should be obtained to rule out
prolactinoma and screening for hemochromatosis
should be considered. Pituitary imaging studies to
evaluate for structural lesions in the hypothalamic–
pituitary region are recommended if the total test-
osterone concentration is < 150 ng⁄dl (2). A karyo-
type should be considered in a young teenager
or infertile man with primary hypogonadism to
diagnose Klinefelter syndrome (2–4).
Treatment
Testosterone formulations
There are a number of options for testosterone
replacement therapy in hypogonadal patients and
these are summarised in Table 9 (2,78,79).
When looking at the treatment options, it is
important to keep in mind that the goal of testoster-
one replacement therapy is to increase blood testos-
terone concentrations to the normal (eugonadal)
range and to match the most appropriate treatment
to the individual patient. The eugonadal range for
adult men has been considered in most studies to be
in the range of 300–1000 ng⁄dl (the AACE recom-
mends 280–800 ng⁄dl), and it is usually considered
best to aim for a testosterone level in the mid-nor-
mal range, avoiding excessive supraphysiological
peaks (3,67,79).
Intramuscular injections
Testosterone injections have been available for at
least 50 years and are usually the cheapest choice
for treatment. The testosterone esters, testosterone
enanthate or testosterone cypionate, are administered
in the ofﬁce or at home by the patient or a desig-
nate. A characteristic of injected testosterone esters is
that, after the injection, the serum testosterone levels
rise to supraphysiological levels, after which they
gradually decline into the hypogonadal range by the
end of the dosing interval. Some patients show paral-
lel variations in breast tenderness, sexual activity,
emotional stability (anger or depression) and general
well-being (fatigue) as the testosterone levels change
over time. The usual frequency of injections is once
Table 8 Conditions with high and low SHBG levels
(2,76)
Increased SHBG
concentrations
Decreased SHBG
concentrations
Ageing Hypothyroidism
Hepatic cirrhosis Obesity; metabolic syndrome
Use of anticonvulsants Type 2 diabetes
Use of estrogens Nephrotic syndrome
Hyperthyroidism Use of glucocorticoids,
progestins, anabolic steroids
HIV infection
Catabolic conditions
(malnutrition;
malabsorption)
SHBG, sex hormone binding globulin.
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terone levels can be reduced by increasing the
frequency of injections to once a week. However, in
some cases, to obtain testosterone concentrations
continuously in the normal range would require
unacceptably frequent injections of small doses.
Mood and sexual function ﬂuctuations can be
reduced by starting with lower doses and titrating
upward.
A long-lasting formulation of testosterone unde-
canoate, another testosterone ester, is available in the
EU and other countries, but not yet in the US. This
is a depot preparation that requires only four injec-
tions a year (80) and has a superior pharmacokinetic
proﬁle compared with the other injectable testoster-
one formulations.
Transdermal patches
These are applied in the night and provide a good
approximation of normal circadian plasma testoster-
one levels. The scrotum has approximately a 40-fold
higher rate of absorption than the forearm and the
ﬁrst testosterone patches were placed on the scrotum,
but these are not so popular because the scrotum has
to be shaved and the adherence is not so good. Non-
genital patches are applied once a day in the evening
to the back, abdomen, thighs or upper arms. Skin
irritation can occur and a preapplication of a corti-
costeroid cream to the skin can help reduce it.
Rarely, skin lesions are also known to occur follow-
ing the use of these patches.
Transdermal gels
These are colourless hydroalcoholic gels of 1% testos-
terone. They are applied once a day to the upper
arms and shoulders or to the abdomen. Gels with a
higher concentration of testosterone are not yet
available in the US, but a 2% testosterone gel is
available in the EU (81,82). These allow the patient
to reduce the total volume of gel applied by about
half compared with a 1% gel.
The gel has a number of advantages including ease
of use, lower incidence of skin irritation compared
with the patch, invisibility of application and ﬂexibil-
ity of dosing. An issue with gels is that testosterone
can be transferred from the patient to his partner or
to children after skin contact. This risk can be mini-
mised by having patients wash their hands with soap
and water after applying the gel, by covering the site
of application with clothing after the gel has dried,
and by washing the application site when skin-to-
skin contact is expected.
Buccal tablets
These are adhesive tablets containing testosterone
that are applied to the gum just above the incisor
teeth. They release testosterone slowly, allowing for
absorption through the gum and cheek surfaces. In
this manner they bypass ﬁrst-pass hepatic metabo-
lism. The tablet must remain in the mouth for a full
12 h and two are needed for the 24 h dosing period.
The incidence of adverse effects is low, although gum
and buccal irritation, and alterations in taste have
been reported.
Subcutaneous pellets
These are amongst the earliest effective formulations
for administering testosterone, dating back to the
1940s. Although not frequently used, they remain
available. The testosterone pellets are usually
implanted under the skin of the lower abdomen
using a trochar and cannula or are inserted into the
gluteus muscle. Six to ten pellets are implanted at
one time and they last 4–6 months, when a new
procedure is required to implant more. Testosterone
pellets currently are the only long-acting testosterone
treatment approved for use in the United States. As
a result of their long-lasting effect and the inconve-
nience of removing them, it is best to use pellets in
men for whom the beneﬁcial effects and tolerance
for testosterone replacement therapy have already
been established.
Table 9 Testosterone formulations available in the United States
Formulation Dose
Intramuscular injections (testosterone enanthate
or testosterone cypionate)
75–100 mg weekly or 150–200 mg every 2 weeks
Transdermal patches (non-scrotal) 2.5–7.5 mg applied nightly for 24 h
Transdermal gels 5–10 g applied daily to upper arms⁄shoulders, or abdomen
(5–10 mg testosterone systemically absorbed)
Buccal tablets 30 mg tablet applied to the buccal mucosa every 12 h
Subcutaneous pellets 6–10, 75 mg pellets implanted subcutaneously every 4–6 months
Oral capsule or tablet (methyl testosterone) Should not be used for the treatment of hypogonadism
because of risk of liver toxicity and hepatocellular carcinoma
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Orally ingested testosterone is inactivated in the liver.
The modiﬁed testosterone 17a-methyl testosterone,
however, has delayed metabolism in the liver.
Although it is an effective oral androgen formulation,
it is not recommended as a testosterone therapy for
hypogonadism because of its hepatotoxic side effects
and its association with long-term development of
liver tumours. Oral testosterone undecanoate, how-
ever, bypasses ﬁrst-pass metabolism through its pref-
erential absorption into the lymphatic system. It is
generally recognised as safe because of the lack of
adverse liver side effects, but it is only available out-
side the US (83).
Symptom relief
Studies with hypogonadal men have demonstrated
that once testosterone levels are restored to a stable
normal range, there is an improvement in libido,
sexual function, mood and energy levels relatively
early in the course of treatment (78,84–86). Over a
period of 6 months there is a reduction in fat body
mass and an increase in lean body mass, and an
improvement in BMD at the hip and spine. Further
improvement in these symptoms may be seen after
longer term use (9,29,32,67). Some studies have
shown that insulin resistance may also improve fol-
lowing testosterone treatment (87,88). This is gener-
ally believed to be as a result of reduction in fat
mass after testosterone therapy. Further research on
this is warranted and testosterone replacement ther-
apy is not currently indicated for treatment of diabe-
tes or metabolic syndrome.
Contraindications and precautions
The contraindications and main precautions of tes-
tosterone therapy are shown in Table 10.
The most important contraindications are for
prostate and breast cancer. Prostate cancer will be
discussed in more detail later, but because androgens
may have a role in promoting the growth of cancers
in these tissues, the presence or suspected presence
of either of these cancers is considered an absolute
contraindication for testosterone therapy.
It is recommended to perform a baseline digital
rectal examinations (DRE) and a baseline PSA level
measurement before starting testosterone therapy for
any man, whatever his age (2,89).
Testosterone is also contraindicated in pregnant or
breast-feeding women. Therefore, testosterone gel
users must consider the possibility of contact with,
and therefore testosterone transfer to, a pregnant or
breast-feeding woman. Care must, therefore, be taken
when prescribing testosterone therapy in the above
circumstances. Men using a testosterone gel should
be advised by their healthcare provider on the ways
of minimising the risk of testosterone transfer to
women and children.
It is likely that, because hypogonadism is associ-
ated with obesity, many hypogonadal patients will
have sleep apnoea. Because testosterone therapy may
worsen sleep apnoea in some patients, there is a need
to ask patients and their partners about any sleep
apnoea symptoms, such as excessive snoring or day-
time tiredness, they may have before they start treat-
ment. Treatment should probably be avoided in
patients with severe, untreated sleep apnoea (2).
Monitoring treatment
Once testosterone replacement therapy has started,
patients need to be carefully monitored. Table 11
shows the principal monitoring requirements for tes-
tosterone therapy as speciﬁed by the Endocrine
Society (2).
As a result of the concerns about prostate cancer
it is important to monitor PSA levels and perform a
DRE regularly during the course of treatment.
At 3 months and 1 year after starting therapy, the
clinical response of testosterone should be evaluated
by documenting serum testosterone levels, monitor-
ing serum PSA levels, and performing a DRE. From
then on PSA levels need to be checked according to
the usual guidelines for prostate cancer screening.
Current American Cancer Society guidelines suggest
prostate cancer screening on an annual basis for any
male over 50 years, for African American males over
45 years, and for higher risk males over 40 years
(multiple ﬁrst-degree relatives affected at an early
age) (90). Any signiﬁcant increase in PSA deserves a
referral to a urologist and treatment should be dis-
continued until evaluated.
Table 10 Contraindications and precautions for
testosterone replacement therapy (2)
Contraindications
Male breast cancer
Prostate cancer (known or suspected)
Known or suspected sensitivity to ingredients used in the
testosterone delivery systems
Precautions
Benign prostatic hyperplasia (BPH); lower urinary tract
symptoms (LUTS)
Oedema in patients with preexisting cardiac, renal, or
hepatic disease
Gynaecomastia
Precipitation or worsening of sleep apnoea
Azoospermia; testicular atrophy
Erythrocytosis
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sis, so a rise in haematocrit is not unusual and it
needs to be monitored. Erythrocytosis incidence is
between 3% and 18% with transdermal formulations
and up to 44% with current intramuscular injections.
Elevated haematocrit values above 54% require
action – usually therapy should be stopped until the
values decrease to a safe level.
Bone mineral density measurement should also be
carried out at baseline because hypogonadism is an
important cause of male osteoporosis. BMD measure-
ment in a male with osteopenia⁄osteoporosis or low
trauma fracture can be repeated in 1–2 years after
testosterone replacement therapy is initiated (2,79).
Benign prostate hyperplasia
Patients with benign prostatic hyperplasia (BPH)
treated with androgens are at an increased risk for
worsening of signs and symptoms of BPH. The
development of BPH requires androgens, but many
studies have failed to show an association with tes-
tosterone treatment. Prostate volume does, however,
increase during testosterone therapy usually in the
ﬁrst 6 months, but this is usually to the normal
volume seen in eugonadal men. The correlation of
voiding symptoms and prostate size is poor, so there
may not be any changes in urine ﬂow rates and
prostate voiding symptoms. However, the increase in
size of the prostate needs to carefully monitored, and
the patient needs to be made aware that there might
be increased voiding symptoms during treatment
(2,4,9,79,89).
Prostate cancer
One of the striking things about a study published in
2007 was that physicians’ number one fear about
initiating testosterone therapy was their perception
that it increases the risk of prostate cancer. More
than 68% of physicians from a worldwide sample
associated testosterone replacement therapy with
more risks than beneﬁts. The authors demonstrated
that, as a result of this, approximately 35% of
hypogonadal patients did not receive treatment (20).
The origins of this concern date back to papers
published in 1941 that reported that androgens stim-
ulated prostate cancer, whereas oestrogen or castra-
tion reduced them (91). Case reports of occult
cancers apparently stimulated to become clinically
relevant cancers by testosterone treatment added to
the concern. In addition, 5 alpha-reductase inhibi-
tors, such as ﬁnasteride and dutasteride, reduce pros-
tate volume and PSA levels. This is consistent with a
role for testosterone in prostate growth.
However, recent analysis has shown that, although
there are case studies of occult conversions, these rep-
resent a very small number of the 200,000 cases of
prostate cancer diagnosed in the United States and
there is no evidence of causality. In fact, prostate can-
cer is correlated with age in men, and older men tend
to have less, not more, testosterone. Likewise, studies
have shown that there is no signiﬁcant difference
between testosterone levels in men with or without
prostate cancer (89,92). So, at the present time, there
is a lack of conclusive evidence that testosterone
therapy in hypogonadal men increases the risk of
Table 11 Endocrine Society Guidelines for the monitoring of testosterone therapy (2)
Start of
treatment
(baseline)
Each
visit 3 months Annually 1–2 years
Symptom response     
Adverse events     
Formulation-speciﬁc AEs  
Testosterone levels   
Haematocrit*     
BMD of
lumbar spine⁄
femoral neck
 
DRE   
PSA   
*If haematocrit is > 54%, stop therapy until haematocrit decreases to a safe level, evaluate the patient for hypoxia and sleep apnoea,
reinitiate therapy with a reduced dose.
For patients with osteoporosis or low trauma fracture, consistent with standard of care.
After 3 months, perform in accordance with guidelines for prostate cancer screening, depending on the age and race of the patient.
Obtain urological consultation under certain conditions.
AEs, adverse events; BMD, bone mineral density; DRE, digital rectal examination; PSA, prostate-speciﬁc antigen.
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promote subclinical cancer to metastatic cancer.
There is evidence, however, that testosterone will
stimulate the growth of existing prostatic cancers
and, of course, existing prostate cancer is contra-
indicated for testosterone therapy (4). A fuller expla-
nation may be that prostate cancer is very sensitive to
changes in serum testosterone when at low
concentrations, but is insensitive at higher concen-
trations because of saturation of the androgen recep-
tors (93).
It is important to mention that the occurrence of
prostate cancer in patients with type 2 diabetes is
lower than that seen in the general population. There
is also the evidence that PSA concentrations are
lower in type 2 diabetes patients and related to
testosterone concentrations (46,94). It is not yet
known if the normal PSA reference ranges should be
lowered for men with type 2 diabetes.
The Institute of Medicine has suggested that to
assess a moderate increase in the risk of prostate can-
cer from testosterone treatment, a large trial requir-
ing 5000 men followed over 3–5 years would be
needed (95). To date a trial like this has not been
performed.
The American Urological Association (AUA) sug-
gests obtaining urological consultation for any of the
following: if the patient’s serum PSA concentration
exceeds 4 ng⁄ml; there is a signiﬁcant rise from one
test to the next; or there is an abnormal DRE result
(96). There is, however, no established consensus
about what constitutes a signiﬁcant rise in PSA levels
or when urological referral should occur for men
with normal PSA levels at baseline. An age-related
guideline for referral if PSA levels exceed 2.5 ng⁄ml
in males under 60 years or 4 ng⁄ml in men over
60 years is often used (97). Usually a velocity change
of 0.75 ng⁄ml or greater in a year is a reason to refer
(96).
Conclusion
Hypogonadism is a common condition in the male
population. Its high prevalence in older men, the
obese and in men with metabolic syndrome, and
type 2 diabetes makes it likely that primary care phy-
sicians meet these patients in their clinics every day.
It is therefore important that physicians are aware of
the major symptoms of the condition and of the
treatment options currently available. It is important
to consider treating symptomatic patients and not
leave them untreated because of anxiety over possible
adverse events from testosterone replacement ther-
apy, after discussing with them the potential beneﬁts
and risks of treatment.
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